Rallybio CVRs Carry High Risk of Expiring Worthless Amid Uncertain Asset Monetization
at www.tipranks.com (Wed, 18-Mar 2:00 AM)
Rallybio and Candid Therapeutics Unveil $505 Million Financing and Merger to Form Well-Capitalized Autoimmune Powerhouse
Market Chameleon (Mon, 2-Mar 10:29 AM)
Rallybio-Candid Merger to Form Candid Therapeutics: $505M Financing to Propel T-Cell Engager Pipeline Through 2030
Market Chameleon (Mon, 2-Mar 9:15 AM)
